Journal of Clinical Endocrinology & Metabolism, Vol 81, 1371-1377, Copyright © 1996 by Endocrine Society

ARTICLES

Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers

H de Boer, GJ Blok, C Popp-Snijders, L Stuurman, RC Baxter and E van der Veen
Department of Endocrinology, Free University Hospital, Amsterdam, The Netherlands.

The optimal dose for GH replacement therapy in GH-deficient (GHD) adults is not known, nor is there a consensus as to which method is the most appropriate for the monitoring of treatment. To establish a general guideline for GH replacement therapy in adults, we evaluated the relationship between the administered GH dose and the achieved serum levels of three GH-dependent serum markers. Serum levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and the acid-labile subunit (ALS) were measured in 46 GHD men participating in a 1-yr, double blind, and placebo-controlled dose- response study. The doses of recombinant human GH ranged from 0.33-3.0 IU/m(2)-day. During GH treatment, dose reduction was necessary because of side-effects in 18 of 46 patients, i.e. in 18% of the patients receiving a maintenance dose of 1 IU/M(2)-day, in 35% of the patients receiving a dose of 2 IU/m(2)-day, and in 67% of the patients receiving a dose of 3 IU/M(2)-day. In the untreated state, serum levels of all three markers were below the normal range in 90% of the patients. The rise in serum marker concentrations during the first month of treatment was dose dependent. Significant increases in IGF-I, IGFBP-3, and ALS levels were observed with a dose as low as 0.33 IU/M(2)-day. The minimal GH dose required for normalization of the serum IGF-I concentration was 0.66 IU/M(2)-day, and it was 1.0 IU/M(2)-day for ALS and IGFBP-3. In patients receiving 2.0 IU/M(2)-day, the mean serum IGF- I concentration rose to an abnormally high level, whereas at this dose, the mean IGFBP-3 and ALS levels were not different from normal. The lower sensitivity of IGFBP-3 and ALS to GH doses in the high range was also apparent during long term treatment. The number of patients who developed IGFBP-3 or ALS levels that exceeded the upper normal limit was substantially smaller than the number of patients with elevated IGF- I concentrations (2, 8, and 19 of 46 patients, respectively). In conclusion, serum IGF-I appears to be the preferred biochemical marker for the detection of GH excess in adults receiving GH replacement therapy, because it is more sensitive than IGFBP-3 and ALS to GH doses in the high range. If normalization of the serum IGF-I concentration is taken as the criterion for optimal GH replacement therapy, the predicted optimal GH dose for GHD men 20 - 40 yr old is 1.4 IU/M(2)- day, and the 95% confidence interval is 1.2-1.6 IU/M(2)-day.

This article has been cited by other articles:

				K. M Morrison, M. Bidlingmaier, S. Stadler, Z. Wu, L. Skriver, and C. J Strasburger Sample pre-treatment determines the clinical usefulness of acid-labile subunit immunoassays in the diagnosis of growth hormone deficiency and acromegaly Eur. J. Endocrinol., March 1, 2007; 156(3): 331 - 339. [Abstract] [Full Text] [PDF]

				T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				A. R. Hoffman, J. E. Kuntze, J. Baptista, H. B. A. Baum, G. P. Baumann, B. M. K. Biller, R. V. Clark, D. Cook, S. E. Inzucchi, D. Kleinberg, et al. Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2048 - 2056. [Abstract] [Full Text] [PDF]

				S. G. Albert and A. D. Mooradian Low-Dose Recombinant Human Growth Hormone as Adjuvant Therapy to Lifestyle Modifications in the Management of Obesity J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 695 - 701. [Abstract] [Full Text] [PDF]

				R. Draghia-Akli, K. K. Cummings, A. S. Khan, P. A. Brown, and R. H. Carpenter Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs J Anim Sci, September 1, 2003; 81(9): 2301 - 2310. [Abstract] [Full Text] [PDF]

				D. C. O'Sullivan, T. A. M. Szestak, and J. M. Pell Regulation of IGF-I mRNA by GH: putative functions for class 1 and 2 message Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E251 - E258. [Abstract] [Full Text] [PDF]

				A. Kehely, P. C. Bates, P. Frewer, M. Birkett, W. F. Blum, P. Mamessier, S. Ezzat, K. K. Y. Ho, G. Lombardi, A. Luger, et al. Short-Term Safety and Efficacy of Human GH Replacement Therapy in 595 Adults with GH Deficiency: A Comparison of Two Dosage Algorithms J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1974 - 1979. [Abstract] [Full Text] [PDF]

				P. Cohen, G. M. Bright, A. D. Rogol, A.-M. Kappelgaard, and R. G. Rosenfeld Effects of Dose and Gender on the Growth and Growth Factor Response to GH in GH-Deficient Children: Implications for Efficacy and Safety J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 90 - 98. [Abstract] [Full Text] [PDF]

				E. M. McConnell, A. B. Atkinson, C. Ennis, D. R. Hadden, D. R. McCance, B. Sheridan, and P. M. Bell The Effects on Insulin Action in Adult Hypopituitarism of Recombinant Human GH Therapy Individually Titrated for Six Months J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5342 - 5347. [Abstract] [Full Text] [PDF]

				W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children Endocr. Rev., August 1, 2001; 22(4): 425 - 450. [Abstract] [Full Text] [PDF]

				P. Marzullo, C. Di Somma, K. L. Pratt, J. Khosravi, A. Diamandis, G. Lombardi, A. Colao, and R. G. Rosenfeld Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3001 - 3008. [Abstract] [Full Text] [PDF]

				M. Arosio, S. Garrone, P. Bruzzi, G. Faglia, F. Minuto, and A. Barreca Diagnostic Value of the Acid-Labile Subunit in Acromegaly: Evaluation in Comparison with Insulin-Like Growth Factor (IGF) I, and IGF-Binding Protein-1, -2, and -3 J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1091 - 1098. [Abstract] [Full Text]

				T. B. Twickler, H. W. Wilmink, P. C. N. J. Schreuder, M. C. Cabezas, P. S. van Dam, H. P. F. Koppeschaar, D. W. Erkelens, and G. M. Dallinga-Thie Growth Hormone (GH) Treatment Decreases Postprandial Remnant-Like Particle Cholesterol Concentration and Improves Endothelial Function in Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4683 - 4689. [Abstract] [Full Text]

				J. A. M. Beentjes, A. van Tol, W. J. Sluiter, and R. P. F. Dullaart Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults J. Lipid Res., June 1, 2000; 41(6): 925 - 932. [Abstract] [Full Text]

				B.-A. Bengtsson and G. Johannsson The Treatment of Growth Hormone Deficiency in Adults J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 933 - 937. [Full Text]

				J. Khosravi, A. Diamandi, J. Mistry, and R. G. Krishna The High Molecular Weight Insulin-Like Growth Factor-Binding Protein Complex: Epitope Mapping, Immunoassay, and Preliminary Clinical Evaluation J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2826 - 2833. [Abstract] [Full Text]

				J. C. ter Maaten, H. de Boer, O. Kamp, L. Stuurman, and E. A. van der Veen Long-Term Effects of Growth Hormone (GH) Replacement in Men with Childhood-Onset GH Deficiency J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2373 - 2380. [Abstract] [Full Text]

				C. Camacho-Hübner, K. A. Woods, F. Miraki-Moud, P. C. Hindmarsh, A. J. Clark, Y. Hansson, A. Johnston, R. C. Baxter, and M. O. Savage Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1611 - 1616. [Abstract] [Full Text]

				H. Olivecrona, A. Hilding, C. Ekström, H. Barle, B. Nyberg, C. Möller, P. J. Delhanty, R. C. Baxter, B. Angelin, T. J. Ekström, et al. Acute and Short-Term Effects of Growth Hormone on Insulin-Like Growth Factors and Their Binding Proteins: Serum Levels and Hepatic Messenger Ribonucleic Acid Responses in Humans J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 553 - 560. [Abstract] [Full Text]

				N. Kawai, S. Kanzaki, S. Takano-Watou, C. Tada, Y. Yamanaka, T. Miyata, M. Oka, and Y. Seino Serum Free Insulin-Like Growth Factor I (IGF-I), Total IGF-I, and IGF-Binding Protein-3 Concentrations in Normal Children and Children with Growth Hormone Deficiency J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 82 - 89. [Abstract] [Full Text]

				A. A. Toogood and S. M. Shalet Growth Hormone Replacement Therapy in the Elderly with Hypothalamic-Pituitary Disease: A Dose-Finding Study J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 131 - 136. [Abstract] [Full Text]

				A. Juul, S. Møller, E. Mosfeldt-Laursen, M. H. Rasmussen, T. Scheike, S. A. Pedersen, K. W. Kastrup, H. Yu, J. Mistry, S. Rasmussen, et al. The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone Deficiency J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4408 - 4415. [Abstract] [Full Text]

				W. M. Drake, D. Coyte, C. Camacho-Hübner, N. M. Jivanji, G. Kaltsas, D. F. Wood, P. J. Trainer, A. B. Grossman, G. M. Besser, and J. P. Monson Optimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary Adults J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3913 - 3919. [Abstract] [Full Text]

				P. Lucidi, M. Lauteri, S. Laureti, R. Celleno, S. Santoni, E. Volpi, G. Angeletti, F. Santeusanio, and P. De Feo A Dose-Response Study of Growth Hormone (GH) Replacement on Whole Body Protein and Lipid Kinetics in GH-Deficient Adults J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 353 - 357. [Abstract] [Full Text]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				R. C. Baxter The Binding Protein's Binding Protein-- Clinical Applications of Acid-Labile Subunit (ALS) Measurement J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3941 - 3943. [Full Text] [PDF]

				H. de Boer and E. A. van der Veen Why Retest Young Adults with Childhood-Onset Growth Hormone Deficiency? J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2032 - 2036. [Full Text] [PDF]

				N. Bravenboer, P. Holzmann, H. de Boer, J. C. Roos, E. A. van der Veen, and P. Lips The Effect of Growth Hormone (GH) on Histomorphometric Indices of Bone Structure and Bone Turnover in GH-Deficient Men J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1818 - 1822. [Abstract] [Full Text] [PDF]

				Y. J. H. Janssen, M. Frolich, and F. Roelfsema A Low Starting Dose of Genotropin in Growth Hormone-Deficient Adults J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 129 - 135. [Abstract] [Full Text] [PDF]

				M. Thoren, A. Hilding, R. C. Baxter, M. Degerblad, I.-L. Wivall-Helleryd, and K. Hall Serum Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit as Serum Markers of Body Composition during Growth Hormone (GH) Therapy in Adults with GH Deficiency J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 223 - 228. [Abstract] [Full Text] [PDF]